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To The Editor: Hepatitis C virus (HCV) infection is a 
leading cause of silent liver inflammation (hepatitis), 
scarring (cirrhosis) and hepatocellular carcinoma.   
Although it is primarily and efficiently transmitted through 
large and repeated percutaneous exposure  to blood and 
blood products, overt percutaneous exposure cannot be 
identified in 10-50% of cases [1]. During the years 2004-
2005, 31618 healthy blood donors (HBD), 157 intravenous 
drug abusers (IDUs) [2], 280 patients of chronic renal 
failure (CRF) on haemodialysis, 550 persons engaged in 
high risk sexual practices (HRSP) [2] and 130 patients of 
chronic liver disease (CLD) attending the tertiary care 
hospital attached to Government Medical College, Amritsar 
(Punjab; North India) were screened for anti- HCV 
antibodies using commercially available third generation 
anti- HCV ELISA kits (HCV Microlisa; J Mitra and Co. Ltd, 
New Delhi, India).  
 
Table 1 shows that the prevalence of HCV antibodies in 
HBD is 1.76%. Hepatitis C accounts for 70-80% post 
transfusion non A-non B hepatitis cases in centres where 
only hepatitis B free blood is transfused [3]. In India, 
screening of blood for anti HCV antibodies is mandatory 
since 2004 [4]. By monitoring and strict enforcement of 
this law , transmission of HCV through blood transfusion 
could be reduced to a minimum. This has already been 
achieved in some western countries [3]. 
 
Table 1: Prevalence of antibodies in healthy blood donors and 
different risk groups 
Group   
Number 
tested  
 
Number 
positive  
% positive  
Healthy blood 
donors  
 
31618  559    1.76  
Chronic renal 
failure patients on 
haemodialysis  
 
280  96  34.3  
Intravenous drug 
users*  
 
157  53  33.75  
Persons of high 
risk sexual 
practices*  
 
550  15  2.72  
Chronic liver 
disease patients  
 
130  17  13.1  
 
Among the various risk groups of patients screened, 
p a t i e n t s  o f  C R F  o n  h a e m o d i a l y s i s  w e r e  f o u n d  t o  b e  a t  
highest risk (34.3% prevalence- Table 1). This could be 
the result of prolonged vascular access and exposure of 
these patients to contaminated medical equipment and 
other infected patients. In IDUs, the observed prevalence 
rate was 33.75% (Table 1) [2]. This high prevalence 
seems to be the result of direct percutaneous exposure 
due to sharing of contaminated needles. It has been 
reported that the seroconversion rate in IDUs is 20% per 
year and long term IDUs are almost invariably HCV 
infected [3]. Among the HRSP group, the positivity was 
2.72% and it showed insignificant difference (p > 0.05) 
from that observed in HBD (1.76%). This indicates that 
sexual transmission is not a substantial contributor in the 
spread of HCV infection in our set-up. However, its 
prevalence of 13.1% in CLD patients shows that HCV 
infection, no doubt, is a major contributor to the burden of 
CLD and cirrhosis in this part of our country 
 
Therefore, we conclude that there is definitely a big pool 
of HCV infected persons in North India who can act as a 
reservoir for its continuous transmission and are at risk of 
developing HCV related chronic disease. Although blood 
supply is being made safe by mandatory screening, the 
risk of HCV infection still remains through the use of non-
sterile/improperly sterilized needles and equipment 
(medical and dental), sharing of needles, razors and tooth 
brushes,  tattooing and other certain body piercing 
practices which are common in this region. Much of this 
could be prevented by implementing infection control 
practices in health care and other settings, proper 
counselling of persons with high risk drug and sexual 
practices and by professional and public health education. 
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